Modified Lectin Cross-Linked Materials for Glucose-Responsive Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current controlled-release drug delivery systems, such as those for insulin in diabetes treatment, fail to release drugs in proportion to molecular indicators like glucose levels, leading to uncontrolled and undesirable slow release, and native lectins used in glucose-responsive systems pose risks due to mitogenicity, causing inflammation and allergic reactions.
Innovation Solution
Development of cross-linked materials with multivalent lectins and covalently or non-covalently linked affinity ligands that compete with glucose for binding sites, reducing mitogenicity while maintaining glucose responsiveness, and chemically modifying lectins to reduce their mitogenic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If native lectins are used in glucose-responsive drug delivery systems, then glucose responsiveness is achieved, but mitogenicity causes inflammation and allergic reactions
Solution Approach 1:
The patent removes the harmful mitogenic property from lectins while preserving their glucose-binding function. This is achieved by chemically modifying lectins to eliminate their ability to bind to carbohydrate receptors on lymphocytes, thereby extracting the harmful aspect while retaining the useful glucose-responsive characteristic.
Solution Approach 2:
The modification is applied locally to specific functional regions of the lectin molecule. By targeting the modification to specific amino acid residues or binding sites, the patent preserves glucose-binding capability in certain regions while eliminating mitogenicity in others, achieving spatial differentiation of function.
2Duration of action of moving object
If controlled-release drug delivery systems are used, then slow release is achieved, but release is not proportional to molecular indicators like glucose levels
Solution Approach 1:
The patent implements a feedback mechanism where the drug release rate is directly controlled by glucose levels in the body. The glucose-responsive lectin-based system detects glucose concentration and adjusts insulin release accordingly, creating a closed-loop control system that mimics physiological regulation.
Solution Approach 2:
The drug delivery system transitions from static slow release to dynamic responsive release. The system's release characteristics change in real-time based on glucose concentration, allowing the release rate to adapt and respond to varying physiological conditions rather than maintaining a constant slow release profile.
3Stability of the object's composition
If mitogenic lectins are used to form cross-linked materials, then structural stability is achieved, but immune responses and cytotoxicity occur
Solution Approach 1:
The patent converts the harmful immune-stimulating property of lectins into a beneficial feature by using the same carbohydrate-binding capability to create glucose-responsive cross-linking. The modified lectins now utilize their natural affinity for carbohydrates to detect glucose and trigger drug release, transforming a harmful immune response mechanism into a useful sensing and actuation mechanism.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution enables controlled release of drugs in response to specific glucose concentrations, minimizing adverse reactions by reducing the mitogenicity of lectins, thus providing a safer and more physiological insulin delivery system.
Implementation Method 1
conjugates are cross-linked within the material as a result of non-covalent interactions between lectins and affinity ligands on different conjugates
Implementation Method 2
affinity ligands which are capable of competing with glucose for binding with at least one of said binding sites
Data Source
AI summary
In one aspect, the disclosure provides cross-linked materials that include multivalent lectins with at least two binding sites for glucose, wherein the lectins include at least one covalently linked affinity ligand which is capable of competing with glucose for binding with at least one of said binding sites; and conjugates that include two or more separate affinity ligands bound to a conjugate framework, wherein the two or more affinity ligands compete with glucose for binding with the lectins at said binding sites and wherein conjugates are cross-linked within the material as a result of non-covalent interactions between lectins and affinity ligands on different conjugates. These materials are designed to release amounts of conjugate in response to desired concentrations of glucose. Depending on the end application, in various embodiments, the conjugates may also include a drug and/or a detectable label.